| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8230957 | International Journal of Radiation Oncology*Biology*Physics | 2011 | 6 Pages |
Abstract
Concurrent bevacizumab and RT did not increase acute locoregional toxicity in comparison with matched control patients who did not receive RT alone. The addition of concurrent RT when treating the intact breast, chest wall, and associated nodal regions in breast cancer seems to be safe and well tolerated.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Sharad M.D., Malay S. Pharm.D., Atif M.D., Lien R.N., Camille M.D., Bruce G. M.D.,